NCT02121899

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Treatment Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients (LUNG CARE Registry)

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 44 (actual)
• Sponsor: Myriad Genetic Laboratories, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006).

Conditions

• Lung Cancer
• NSCLC
• NSCLC Adenocarcinoma

Timeline

• Start date: 2015-04-01
• Primary completion: 2017-06-30
• Completion: 2017-07-31
• First posted: 2014-04-24
• Last updated: 2017-09-05

Locations

1 site across 1 country: United States